These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 9783942)

  • 21. Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black american men but not in white men: results from a consecutive series of 914 men.
    Latchamsetty KC; Kim J; Porter CR
    J Urol; 2006 Mar; 175(3 Pt 1):913-7; discussion 917. PubMed ID: 16469578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Problems with prostate specific antigen screening for prostate cancer in the primary healthcare setting in South Africa.
    Heyns CF; Mathee S; Isaacs A; Kharwa A; De Beer PM; Pretorius MA
    BJU Int; 2003 Jun; 91(9):785-8. PubMed ID: 12780832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.
    Eastham JA; Carver B; Katz J; Kattan MW
    Prostate; 2002 Mar; 50(4):236-40. PubMed ID: 11870801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.
    Espaldon R; Kirby KA; Fung KZ; Hoffman RM; Powell AA; Freedland SJ; Walter LC
    Urology; 2014 Mar; 83(3):599-605. PubMed ID: 24439009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.
    Arai Y; Maeda H; Ishitoya S; Okubo K; Okada T; Aoki Y
    J Urol; 1997 Sep; 158(3 Pt 1):861-4. PubMed ID: 9258099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.
    Bissonette EA; Fulmer BR; Petroni GR; Moul JW; Theodorescu D
    J Urol; 2001 Oct; 166(4):1328-31; discussion 1331-2. PubMed ID: 11547067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-specific reference ranges for serum prostate-specific antigen in black men.
    Morgan TO; Jacobsen SJ; McCarthy WF; Jacobson DJ; McLeod DG; Moul JW
    N Engl J Med; 1996 Aug; 335(5):304-10. PubMed ID: 8663870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.
    Whittemore AS; Cirillo PM; Feldman D; Cohn BA
    J Urol; 2005 Sep; 174(3):872-6; discussion 876. PubMed ID: 16093978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
    Verges DP; Dani H; Sterling WA; Weedon J; Atallah W; Mehta K; Schreiber D; Weiss JP; Karanikolas NT
    J Natl Med Assoc; 2017 Spring; 109(1):49-54. PubMed ID: 28259216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
    Tewari A; Horninger W; Badani KK; Hasan M; Coon S; Crawford ED; Gamito EJ; Wei J; Taub D; Montie J; Porter C; Divine GW; Bartsch G; Menon M
    BJU Int; 2005 Jul; 96(1):29-33. PubMed ID: 15963115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
    Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial variation in prostate specific antigen in a large cohort of men without prostate cancer.
    Eastham JA; Sartor O; Richey W; Moparty B; Sullivan J
    J La State Med Soc; 2001 Apr; 153(4):184-9. PubMed ID: 11394329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.